LFD-200

Phase 1Small molecule

LLifordi Immunotherapeutics, Inc.

LFD-200 is one of 33 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Preclinical

47 2

Actemra

Rituxan

61 4

Simponi

Johnson & Johnson

Preclinical

19 5

Remicade

OOrganon and Co

Preclinical

43 6

Enbrel

IImmunex

Preclinical

64 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Actos

Takeda

Preclinical

2 9

Celexa

AbbVie

Preclinical

1 10

Cataflam

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Rheumatoid Arthritis

NCT07207954

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis

Recruiting·LLifordi Immunotherapeutics, Inc.·Phase 1·NCT07207954·176 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LFD-200. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LFD-200 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LFD-200. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lifordi Immunotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: LLifordi Immunotherapeutics, Inc.

LFD-200

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News